Brind.

Fulcrum Therapeutics, based in Cambridge, MA, is listed on the Nasdaq exchange.

3 reports, 1 independent Updated Aug 9
Gone quiet
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Fulcrum Therapeutics, based in Cambridge, MA, is listed on the Nasdaq exchange.

Who's involved

What this event is mainly about
Fulcrum Therapeutics (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Fulcrum Therapeutics, based in Cambridge, MA, has been listed on Nasdaq since August 2025.1 source
  2. Fulcrum Therapeutics reported trial results for pociredir in the PIONEER trial.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage bi
  • GlobeNewswireFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 ― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredi
  • GlobeNewswireFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage bi